Dr. Rajeev Saggar - 17 Aug 2026 Form 4 Insider Report for Liquidia Corp (LQDA)

Reporting relationship: Chief Medical Officer
Issuer ticker: LQDA
Reported as of: 17 Aug 2026
Net transaction value: -$5,972,206
SEC form: 4
Accepted by SEC: 19 Aug 2026, 18:21:25 UTC
Prior SEC filing: 14 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Dr. Rajeev Saggar

Key filing fact

Dr. Rajeev Saggar filed Form 4 for Liquidia Corp (LQDA) on 19 Aug 2026.

Key facts

This page summarizes Dr. Rajeev Saggar's Form 4 filing for Liquidia Corp (LQDA).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 19 Aug 2026, 18:21.

Change

Previous filing in this sequence was filed on 14 Jul 2026.
Current net transaction value: -$5,972,206.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001935638 Primary reporting owner

Saggar Rajeev

Relationship: Chief Medical Officer
Address: 419 DAVIS DRIVE, SUITE 100, MORRISVILLE
Signature: /s/ Dr. Rajeev Saggar
Signature date: 19 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LQDA transaction

Common Stock

Sale

Transaction value: $2,269,381
Shares: -29,534
Change %: -17%
Price: $76.84
Shares after: 142,265
Date: 17 Aug 2026
Ownership: Direct
Footnotes: F1, F2

LQDA transaction

Common Stock

Options Exercise

Transaction value
Shares: +50,000
Change %: +35%
Price: $3.73^*
Shares after: 192,265
Date: 19 Aug 2026
Ownership: Direct
Footnotes: F2

LQDA transaction

Common Stock

Sale

Transaction value: $3,702,825
Shares: -50,000
Change %: -26%
Price: $74.06
Shares after: 142,265
Date: 19 Aug 2026
Ownership: Direct
Footnotes: F2, F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LQDA transaction Derivative

Non-Qualified Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -50,000
Change %: -25%
Price: $0.000000^*
Shares after: 150,000
Date: 19 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price: $3.73
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Price is the volume weighted average price of all transactions made by the Reporting Person on the transaction date for prices ranging from $76.76 to $77.13. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F2

Includes (i) 10,416 unvested restricted stock units ("RSUs") of the 83,333 RSUs granted to the Reporting Person on January 11, 2023, (ii) 21,184 unvested RSUs of the 56,492 RSUs granted to the Reporting Person on January 11, 2024, (iii) 44,862 unvested RSUs of the 71,780 RSUs granted to the Reporting Person on January 11, 2025, (iv) 32,955 RSUs granted to the Reporting Person on January 16, 2026, none of which have vested as of the date of this Form 4 and (v) 2,650 shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan.

Footnote F3

Represents the subsequent sale of the underlying shares from the exercise of stock options reported on this Form 4.

Footnote F4

Price is the volume weighted average price of all transactions made by the Reporting Person on the transaction date for prices ranging from $74.00 to $74.60. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F5

The option vested over a four-year period with 25% vesting on July 18, 2023 and the remaining 75% vesting ratably on a monthly basis over three years thereafter and became fully vested on July 18, 2026.